Theralase Technologies completes public offering of units

2 minute read
01 March 2015

On March 3, 2015, Theralase Technologies Inc. (TSXV: TLT) (PINKSHEETS: TLTFF) announced that it had closed its previously announced public offering of units, having issued an aggregate of 18,181,817 units at a price of $0.44 per unit for aggregate gross proceeds of approximately $8,000,000. Each unit consists of one common share of Theralase and one common share purchase warrant. Each warrant entitles the holder to acquire an additional common share at a price of $0.54 for a period of 60 months following the date of issuance.

The units were qualified for sale by way of a prospectus supplement dated February 25, 2015 to Theralase’s short form base shelf prospectus dated January 9, 2015, which was filed in the Provinces of British Columbia, Alberta and Ontario.

Euro Pacific Canada Inc. acted as agent in connection with the offering. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS), acted as exclusive U.S. placement agent.

Gowlings was counsel to Euro Pacific Canada with a team that included Paul Fornazzari, Jeff Zabalet and David Morrison, with the assistance of student-at-law Leslie Blumer.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.